Intravenous LIGNOcaine for the POstoperative Sore Throat (LIGNO-POST)
Intravenous LIGNOcaine for the POstoperative Sore Throat: A Double-blinded Randomised Placebo-controlled Trial (LIGNO-POST Trial)
Patients often encounter unpleasant sore throat after surgery when wake up from general anaesthesia and pulling off breathing tube. Lignocaine is a medication used in anaesthesia for the properties of analgesia and anti-inflammation. Other studies suggested that lignocaine spray/ gel can reduce the postoperative sore throat after extubation in patients undergoing surgery. However, it can reduce the gag reflex, resulting in higher risk of aspiration after surgery. Therefore, this randomized, double-blind, placebo-controlled trial is designed to determine whether giving intravenous lignocaine toward the end of the surgery before extubation can reduce postoperative sore throat and discomfort after surgery. It is hypothesized that intravenous lignocaine can reduce postoperative sore throat in patients undergoing general anaesthesia.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Postoperative sore throat (POST) is a common and discomfort adverse event following general anaesthesia with orotracheal intubation, with reported incidences ranging from 30% to 70%. It is characterized by pain or discomfort at the larynx or pharynx during postoperative period in the recovery area, which can affect the overall perioperative experience and patient satisfaction. The pathophysiology of POST is believed due to mechanical trauma to the pharyngeal and laryngeal mucosa during intubation, cuff-related pressure injury, and airway inflammation that cause postoperative throat symptoms. Several non-pharmacological and pharmacological measures such as lozenges, gargles, lignocaine spray and steroid injection have been experimented with mixed findings.
Lignocaine is a local anaesthetic agent, which has the properties of analgesia and anti-inflammatory effect via the blockade of sodium channel receptor. Lignocaine spray at the throat is believed to reduce the severity of POST at various concentration (2%, 5% and 10%). However, studies reported that some of the additives agents (methanol, ethanol) in the lignocaine spray have irritating side effects to damage tracheal mucosa, negating the effect of topical lignocaine on the incidence of POST. In addition, topicalized lignocaine reduces the gag reflex if given too late before extubation, resulting in higher risk of aspiration in the recovery area.
In a routine general anaesthesia, intravenous dexamethasone is administered as an analgesic adjunct and anti-inflammatory to minimize airway edema. Administering intravenous lignocaine prior to extubation is believed to provide analgesic effect to reduce incidence of POST and postoperative cough after general anaesthesia. However, the evidence regarding its effect on POST remains limited and inconsistent, particularly when administered near the time of emergence from general anaesthesia.
Therefore, this randomized, double-blind, placebo-controlled trial is aimed to examine the use of intravenous lignocaine prior to extubation in the reduction of POST in surgical patients undergoing oral intubation during general anaesthesia in University Malaya Medical Centre.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
- Jméno: Ka Ting Ng, MBChB (Edinburgh)
- Telefonní číslo: +60379492411
- E-mail: katingng1@um.edu.my
Studijní místa
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malajsie, 59100
- Universiti Malaya Medical Centre
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Adults aged 18-65 years.
- American Society of Anaesthesiologists (ASA 1-2).
- Scheduled for elective non-airway surgery requiring general anaesthesia with orotracheal intubation of anticipated duration ≥ 90 minutes.
- Able to understand the patient information sheet (in English or Bahasa Malaysia) and provide written informed consent.
Exclusion Criteria:
- ASA physical status III-V.
- Body mass index < 18 or > 40 kg/m².
- Known hypersensitivity to amide local anaesthetics, including lignocaine.
- Anticipated difficult airway (Mallampati III-IV, mouth opening < 3 cm, restricted neck extension, thyromental distance < 6 cm).
- Upper respiratory tract infection within the preceding 2 weeks; chronic cough; pre-existing sore throat or hoarseness.
- Airway, head-and-neck, dental, or thoracic surgery; surgery requiring transoesophageal echocardiography.
- History of significant cardiac arrhythmia, second- or third-degree heart block, or hepatic impairment (Child-Pugh B or C).
- Pregnancy or lactation.
- Inability to perform self-report outcome assessment owing to cognitive impairment or language barrier.
- Concurrent systemic lignocaine or anti-arrhythmic class I therapy.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Group L (lignocaine)
|
IV lignocaine 1.5 mg/kg, calculated on lean body weight (LBW). |
|
Komparátor placeba: Group P (placebo)
|
0.9% normal saline |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of postoperative sore throat (POST)
Časové okno: 1-hour, 6-hour, 24-hour after surgery
|
Patient-reported pain/discomfort in throat (yes/no) on standardised question. |
1-hour, 6-hour, 24-hour after surgery
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Severity of POST
Časové okno: 1-hour, 6-hour, 24-hour after surgery
|
NRS 0-10 (0 = none, 10 = worst imaginable). |
1-hour, 6-hour, 24-hour after surgery
|
|
Incidence and severity of postoperative cough
Časové okno: 1-hour, 6-hour, 24-hour after surgery
|
Observation of cough in post anaesthesia care unit (yes/no); 4-point scale: 0 none, 1 mild (single), 2 moderate (> 1 episode), 3 severe (constant). |
1-hour, 6-hour, 24-hour after surgery
|
|
Incidence of post-extubation hoarseness
Časové okno: 1-hour, 6-hour, 24-hour after surgery
|
Stout's 4-point grading: 0 no hoarseness, 1 mild hoarseness (only noticed by patient), 2 severe hoarseness (noticed by medical personnel), 3 aphonia (total inability to speak) |
1-hour, 6-hour, 24-hour after surgery
|
|
Patient satisfaction
Časové okno: 24-hour after surgery
|
NRS 0-10 (0 = not satisfy, 10 = very satisfy) |
24-hour after surgery
|
|
Adverse events of intravenous lignocaine
Časové okno: During surgery and 1-hour after surgery in post anaesthesia care unit
|
haemodynamic events (HR < 50 or > 100, MAP < 65 or > 110); seizure, perioral numbness, dizziness, tinnitus. |
During surgery and 1-hour after surgery in post anaesthesia care unit
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Obecné publikace
- El-Boghdadly K, Bailey CR, Wiles MD. Postoperative sore throat: a systematic review. Anaesthesia. 2016 Jun;71(6):706-17. doi: 10.1111/anae.13438. Epub 2016 Mar 28.
- Hung NK, Wu CT, Chan SM, Lu CH, Huang YS, Yeh CC, Lee MS, Cherng CH. Effect on postoperative sore throat of spraying the endotracheal tube cuff with benzydamine hydrochloride, 10% lidocaine, and 2% lidocaine. Anesth Analg. 2010 Oct;111(4):882-6. doi: 10.1213/ANE.0b013e3181d4854e. Epub 2010 Mar 19.
- Yang SS, Wang NN, Postonogova T, Yang GJ, McGillion M, Beique F, Schricker T. Intravenous lidocaine to prevent postoperative airway complications in adults: a systematic review and meta-analysis. Br J Anaesth. 2020 Mar;124(3):314-323. doi: 10.1016/j.bja.2019.11.033. Epub 2020 Jan 28.
- Taskin K, Geyik FD, Arslan G, Sezen O, Cevik B. Efficacy of lidocaine via trachospray in postoperative sore throat and hemodynamic response to intubation: a randomized controlled trial. BMC Anesthesiol. 2025 Mar 20;25(1):133. doi: 10.1186/s12871-025-03004-2.
- Li H, Yue Y, Qu Y, Mu D. Lidocaine for postoperative sore throat: a meta-analysis of randomized controlled trials. Minerva Anestesiol. 2020 May;86(5):546-553. doi: 10.23736/S0375-9393.20.14170-1. Epub 2020 Jan 28.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Neurologické projevy
- Stomatognátní onemocnění
- Nemoci nervového systému
- Patologické procesy
- Infekce dýchacích cest
- Infekce
- Nemoci dýchacích cest
- Poruchy dýchání
- Otorinolaryngologická onemocnění
- Příznaky a symptomy, Respirační
- Faryngeální onemocnění
- Nemoci hrtanu
- Poruchy hlasu
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Kašel
- Pooperační komplikace
- Chrapot
- Zánět hltanu
- Farmaceutické přípravky
- Krystaloidní roztoky
- Izotonická řešení
- Řešení
- Solný roztok
Další identifikační čísla studie
- V1.1
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Requests for de-identified data from qualified researchers may be considered by the principal investigator on a case-by-case basis, subject to approval by the ethics committee.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .